Chargement en cours...
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy
BACKGROUND: Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immuno...
Enregistré dans:
| Publié dans: | J Natl Cancer Inst |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8204709/ https://ncbi.nlm.nih.gov/pubmed/30924863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz049 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|